» Articles » PMID: 28174259

Proinflammatory Cytokines Predict the Incidence and Progression of Distal Sensorimotor Polyneuropathy: KORA F4/FF4 Study

Overview
Journal Diabetes Care
Specialty Endocrinology
Date 2017 Feb 9
PMID 28174259
Citations 51
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: Experimental and epidemiological studies have implicated inflammatory processes in the pathogenesis of distal sensorimotor polyneuropathy (DSPN), but prospective studies are lacking. We hypothesized that biomarkers of inflammation predict the development and progression of DSPN in a population-based cohort.

Research Design And Methods: This study was based on participants aged 62-81 years from the Cooperative Health Research in the Region of Augsburg (KORA) F4/FF4 cohort, with a mean follow-up of 6.5 years. The predictive value of systemic levels of eight biomarkers of inflammation was assessed for incident DSPN in 133 incident case subjects and 397 individuals without incident DSPN, and for DSPN progression in 57 patients with prevalent DSPN at both time points.

Results: Higher hs-CRP, interleukin (IL)-6, tumor necrosis factor (TNF)-α, IL-1 receptor antagonist (IL-1RA), and soluble intercellular adhesion molecule (sICAM-1) and lower adiponectin levels were associated with incident DSPN in age- and sex-adjusted analysis; IL-18 and omentin were not. IL-6 (odds ratio 1.31 [95% CI 1.00-1.71]) and TNF-α (odds ratio 1.31 [95% CI 1.03-1.67]) remained associated with incident DSPN after adjusting for known DSPN risk factors. The addition of both cytokines to a clinical risk model improved model fit and reclassification. sICAM-1 and IL-1RA were positively associated with progression of DSPN.

Conclusions: Systemic subclinical and vascular inflammation predicted both the onset and progression of DSPN over 6.5 years in an older general population. Thus modulation of inflammatory processes may be relevant to prevent and/or treat diabetic neuropathy.

Citing Articles

Nonpharmaceutical treatment of distal sensorimotor polyneuropathy in diabetic patients: an unblinded randomized clinical trial.

Strobel A, Laputsina V, Heinze V, Schulz S, Wienke A, Reer M BMC Complement Med Ther. 2025; 25(1):93.

PMID: 40050870 PMC: 11887202. DOI: 10.1186/s12906-025-04830-0.


Influence of autonomic neuropathy, systemic inflammation and other clinical parameters on mortality in dialysis patients.

Schramm M, Schramm C, Hoppe J, Trautner M, Hinz M, Mitzner S Clin Kidney J. 2025; 18(2):sfae416.

PMID: 39981139 PMC: 11840246. DOI: 10.1093/ckj/sfae416.


Phenotype-based clusters, inflammation and cardiometabolic complications in older people before the diagnosis of type 2 diabetes: KORA F4/FF4 cohort study.

Huemer M, Spagnuolo M, Maalmi H, Wagner R, Bonhof G, Heier M Cardiovasc Diabetol. 2025; 24(1):83.

PMID: 39972466 PMC: 11841139. DOI: 10.1186/s12933-025-02617-8.


Role for neurological and immunological resilience in the pathway of the aging muscle powerpenia: InCHIANTI study longitudinal results.

Pellegrino R, Paganelli R, Di Iorio A, Candeloro M, Volpato S, Bandinelli S Geroscience. 2025; .

PMID: 39885114 DOI: 10.1007/s11357-025-01536-6.


Interpretable multimodal machine learning (IMML) framework reveals pathological signatures of distal sensorimotor polyneuropathy.

Nguyen P, Garger D, Lu D, Maalmi H, Prokisch H, Thorand B Commun Med (Lond). 2024; 4(1):265.

PMID: 39681608 PMC: 11649904. DOI: 10.1038/s43856-024-00637-1.